Last reviewed · How we verify
raltegravir and etravirine — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
raltegravir and etravirine (raltegravir and etravirine) — ANRS, Emerging Infectious Diseases.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| raltegravir and etravirine TARGET | raltegravir and etravirine | ANRS, Emerging Infectious Diseases | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- raltegravir and etravirine CI watch — RSS
- raltegravir and etravirine CI watch — Atom
- raltegravir and etravirine CI watch — JSON
- raltegravir and etravirine alone — RSS
Cite this brief
Drug Landscape (2026). raltegravir and etravirine — Competitive Intelligence Brief. https://druglandscape.com/ci/raltegravir-and-etravirine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab